Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 405,715 shares of the company’s stock after selling 731 shares during the quarter. Epoch Investment Partners Inc. owned about 1.31% of Medpace worth $167,094,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MEDP. Signaturefd LLC grew its stake in shares of Medpace by 4.9% during the second quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after acquiring an additional 26 shares in the last quarter. Wealth Alliance grew its stake in Medpace by 2.9% during the 2nd quarter. Wealth Alliance now owns 970 shares of the company’s stock valued at $399,000 after purchasing an additional 27 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in Medpace by 0.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock worth $1,787,000 after purchasing an additional 32 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its position in shares of Medpace by 5.3% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock valued at $316,000 after purchasing an additional 39 shares in the last quarter. Finally, Journey Advisory Group LLC boosted its stake in shares of Medpace by 1.9% during the 2nd quarter. Journey Advisory Group LLC now owns 2,390 shares of the company’s stock valued at $984,000 after buying an additional 44 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Down 0.9 %

Shares of MEDP stock opened at $365.70 on Friday. The business has a 50 day moving average of $378.15 and a two-hundred day moving average of $391.95. The company has a market cap of $11.33 billion, a P/E ratio of 37.28, a PEG ratio of 1.74 and a beta of 1.35. Medpace Holdings, Inc. has a 52 week low of $227.21 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, July 22nd. The company reported $2.75 EPS for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The firm had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same period in the prior year, the business earned $1.93 EPS. The firm’s revenue was up 14.6% on a year-over-year basis. Analysts expect that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Robert W. Baird dropped their price target on shares of Medpace from $430.00 to $413.00 and set an “outperform” rating for the company in a research note on Friday. TD Cowen dropped their target price on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research report on Wednesday, July 24th. Mizuho began coverage on Medpace in a report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price objective for the company. Finally, Guggenheim reduced their target price on Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a report on Wednesday, July 24th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $420.88.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.